There have been no reports of illness or adverse reactions from consumption of the recalled burritos, but FSIS recommends ...

The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on ...

An announcement from NFI Group Inc ( ($TSE:NFI) ) is now available. NFI Group Inc. and GILLIG LLC have formed a 50/50 joint venture to acquire the ...

Iopofosine I 131 is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...

Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth . Jupiter, FL, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc ...

SAIC Director and Seasoned Government Services Executive James Reagan Appointed Interim CEOCompany Reaffirms Fiscal Year 2026 ...

1. About lecanemab (generic name, brand name: LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

The Islamabad High Court (IHC) has sought a detailed response from the Capital Development Authority (CDA) and the Municipal Corporation Islamabad (MCI) over a petition challenging the alleged killing ...

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and ...

Viehbacher, “Biogen”) announced today that LEQEMBI ® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by ...

SAIC Director and Seasoned Government Services Executive James Reagan Appointed Interim CEOCompany Reaffirms Fiscal Year 2026 GuidanceRESTON, Va., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Science Application ...